Episode Details

Hims and Hers Health Q1 2026 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $21.98 - HOLD - BUY below $18.00 with $14.00 stop - AVOID above $35.00 TRIGGER: Q3 EBITDA margin above 9% AND subscriber growth above 20% WINDOW: Through Q3 2026 earnings (November 2026) TRACKER: charged-alpha.com/calls/HIMS WALL STREET CONSENSUS - Ratings: 2 Strong Buy / 4 Buy / 9 Hold / 2 Sell / 0 Strong Sell - HOLD - Median 12-month price target: $32.00 (range $15 - $65) - Charged Alpha vs consensus: ALIGNED THESIS Hims & Hers is transitioning from a high-margin compounded-GLP-1 telehealth pure-play to a lower-margin branded GLP-1 distribution partner with Novo Nordisk - the unit economics step down before they stabilize. Bull lever: Branded GLP-1 stabilizes at 35-40% gross margin by Q4. Subscribers compound to 3.0 million by FY27. Mental health and primary care segments scale as cross-sell. Key risk: FDA enforcement on remaining compounded channels disrupts revenue. Branded GLP-1 margin stays below 30%. Subscriber churn accelerates as pricing rises. QUALITY CHECK - Management quality grade: C+ (Dudum team built HIMS into a scaled telehealth brand but the GLP-1 strategy switch caught the market by surprise. Capital allocation reasonable; SBC 12.8 percent of revenue is high for a smaller-cap. Two FY26 guide cuts in three quarters dings the credibility account.) - Earnings quality grade: C+ (FCF 53 million versus net loss 92 million inflates the cash-to-earnings ratio. SBC 12.8 percent of revenue dilutes per-share metrics. Inventory build 35 million YoY - likely branded GLP-1 stocking ahead of demand ramp.) CHAPTERS 0:00 Hook 0:44 The Print 1:36 The Trend 2:25 The Segments 3:24 The FCF Bridge 4:18 Guidance & The Narrative Diff 5:21 Peer Dot-Plot 6:18 Management & Earnings Quality 7:34 The Call - Verdict (price-aware + consensus) 8:27 The Call - Supporting Evidence KEY METRICS - Q1 2026 - Revenue: $0.61B (+3.0% YoY, missed estimate by 1.9%) - Adjusted EPS: $-0.18 (vs $0.04 est, missed by 550.0%) - Operating margin: -2.7% - Free cash flow: $0.05B (8.7% margin) GUIDANCE FY2026 revenue guide CUT to 2.55-2.65 billion dollars from prior 2.70-2.80. Q2 revenue guidance 600-620 million missed consensus of 640 million by 4.7 percent. EBITDA margin compressed to 8-10 percent from prior 12-14. The cut directly reflects branded GLP-1 margin reality. NARRATIVE DIFF - what changed in management tone - Prior call (2026-02-23 (Q4 2025 call)): "Our compounded GLP-1 offering continues to drive strong subscriber acquisition with industry-leading unit economics." - Current call (2026-05-12 (Q1 2026 call)): "Q1 reflects the transition from compounded to branded GLP-1 following our partnership with Novo Nordisk. We expect margin compression to persist through Q3 before stabilizing. Long-term subscriber economics remain compelling." - Sentiment shift: negative DATA SOURCES - FMP (financialmodelingprep.com) - Hims and Hers Health Q1 2026 Press Release (2026-05-12) - Q1 2026 Earnings Call commentary DISCLAIMER This is for informational and entertainment purposes only. Not financial advice. Charged Alpha does not have a position in HIMS. Do your own research before any investment decision. #HIMS #HimsandHersHealth #earnings #investing #stocks #ChargedAlpha